China Pharma Holdings (CPHI) Consolidated Net Income: 2009-2025
Historic Consolidated Net Income for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$651,482.
- China Pharma Holdings' Consolidated Net Income rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.76%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
- Per China Pharma Holdings' latest filing, its Consolidated Net Income stood at -$651,482 for Q3 2025, which was down 23.30% from -$528,367 recorded in Q2 2025.
- China Pharma Holdings' 5-year Consolidated Net Income high stood at -$475,976 for Q1 2023, and its period low was -$1.4 million during Q2 2024.
- In the last 3 years, China Pharma Holdings' Consolidated Net Income had a median value of -$785,572 in 2025 and averaged -$889,146.
- In the last 5 years, China Pharma Holdings' Consolidated Net Income slumped by 6,418.56% in 2021 and then skyrocketed by 63.26% in 2025.
- Over the past 5 years, China Pharma Holdings' Consolidated Net Income (Quarterly) stood at -$980,719 in 2021, then dropped by 28.90% to -$1.3 million in 2022, then climbed by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then soared by 41.72% to -$651,482 in 2025.
- Its Consolidated Net Income was -$651,482 in Q3 2025, compared to -$528,367 in Q2 2025 and -$785,572 in Q1 2025.